IMAC Holdings Completes First Infusion of Stem Cells in Clinical Study for the Treatment of Bradykinesia Due to Parkinson’s Disease

[Farooqji]

The first infusion was delivered on December 29, 2020, by trial lead investigator Ricardo Knight, M.D., M.B.A. at the Company’s Brentwood, Tennessee facility. The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, will be conducted at three of IMAC’s clinical centers in Chesterfield, Missouri, Paducah, Kentucky, and Brentwood, Tennessee. The trial will be divided into three groups: (1) five patients with bradykinesia due to Parkinson’s disease will receive a low dose, intravenous infusion of stem cells, (2) five patients will receive a medium intravenous dose, and (3) five patients will receive a high intravenous dose. All groups will be tracked for 12 months. IMAC’s medical doctors and physical therapists at the clinical sites have been trained to administer the treatment and manage the therapy.

globenewswire.com/news-rele...

[Xenos]

Thanks for sharing, but that IMAC company looks like scam to me.

I hope I'm wrong.

[Farooqji]

Dosing Begins in Phase 1 Trial of Stem Cell Therapy for Bradykinesia

parkinsonsnewstoday.com/202...